ASCO GI

Latest ASCO GI News

Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer

SAN FRANCISCO -- Adding the novel anti-TIGIT monoclonal antibody tiragolumab plus atezolizumab

Derick Alison Derick Alison

Long-Term Data Affirm First-Line Immunotherapy for Advanced Esophageal Cancer

SAN FRANCISCO -- A chemoimmunotherapy combination significantly improved long-term survival in advanced

Derick Alison Derick Alison
adbanner